PDCD1 and cancer: ADAR1’s role in innate immunity isnow well established,and ADAR1 has also been shown to be an important therapeutic targetin cancer treatment, in particular in those types of cancer that havean increased ISG transcript signature.68 A reduction in ADAR1 activity has been shown to augment the responseto checkpoint inhibitor anti-PD-L1/PD-1 (programmed cell death ligand1) antibodies69 as reduced RNA editingactivates the RLR pathway and IFN response thus overcoming immunotherapyresistance.